Filters: keyword is Mod [Clear All Filters]
- 2009
Changes in GABAA receptor properties in amygdala kindled animals: in vivo studies using [11C]flumazenil and positron emission tomography,
Epilepsia, vol. 50, no. 1, pp. 88-98.
Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex,
Anesthesiology, vol. 110, no. 1, pp. 95-105.
- 2008
Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model,
J Psychiatr Res, vol. 42, no. 14, pp. 1189-97.
Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy,
J Psychiatr Res, vol. 42, no. 12, pp. 1000-9.
The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments,
J Pharmacol Toxicol Methods, vol. 57, no. 2, pp. 114-30.
Mechanistic model for the acute effect of fluvoxamine on 5-HT and 5-HIAA concentrations in rat frontal cortex,
Eur J Pharm Sci, vol. 33, no. 3, pp. 217-29.
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients,
Clin Pharmacol Ther, vol. 83, no. 3, pp. 443-51.
Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model,
J Pharmacol Exp Ther, vol. 324, no. 3, pp. 1234-42.
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients,
Eur J Clin Pharmacol, vol. 64, no. 3, pp. 329-34.
Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics,
Eur J Pharm Sci, vol. 34, no. 2-3, pp. 149-63.
Pharmacokinetic-pharmacodynamic modelling of fluvoxamine 5-HT transporter occupancy in rat frontal cortex,
Br J Pharmacol, vol. 154, no. 6, pp. 1369-78.
Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats,
Pharm Res, vol. 25, no. 1, pp. 183-93.
Prediction of attack frequency in migraine treatment,
Cephalalgia, vol. 28, no. 8, pp. 847-55.
Extensions to the visual predictive check to facilitate model performance evaluation,
J Pharmacokinet Pharmacodyn, vol. 35, no. 2, pp. 185-202.
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research,
Trends Pharmacol Sci, vol. 29, no. 4, pp. 186-91.
Relevance of absorption rate and lag time to the onset of action in migraine,
Clin Pharmacokinet, vol. 47, no. 2, pp. 139-46.
- 2007
Pharmacokinetic-pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior,
Eur J Pharm Sci, vol. 32, no. 3, pp. 200-8.
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats,
J Pharmacol Exp Ther, vol. 321, no. 2, pp. 598-607.
Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?,
Epilepsia, vol. 48, no. 3, pp. 412-34.
Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats,
J Pharmacol Toxicol Methods, vol. 56, no. 1, pp. 72-8.
Decreased Efficacy of GABAA-receptor modulation by midazolam in the kainate model of temporal lobe epilepsy,
Epilepsia, vol. 48, no. 7, pp. 1378-87.
Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG,
Br J Pharmacol, vol. 151, no. 5, pp. 713-20.
Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers,
Clin Pharmacol Ther, vol. 81, no. 1, pp. 50-8.
Population pharmacokinetic model of fluvoxamine in rats: utility for application in animal behavioral studies,
Eur J Pharm Sci, vol. 30, no. 1, pp. 45-55.
Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update,
Eur J Pharm Sci, vol. 30, no. 2, pp. 107-12.



